Please assess the completion status of the following clinical trial:

Trial Title: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PNH~* Clinically Evident EVH defined by:~  * Anemia (Hgb ≤9.5 gram/deciliter) with absolute reticulocyte count ≥120 x 10\^9/liter~* Receiving an approved C5 inhibitor for at least 6 months prior to Day 1~* Platelet count ≥30,000/microliters (µL)~* Absolute neutrophil counts ≥500/μL~* Documentation of/or willingness to receive vaccinations for N. meningiditis and prophylactic antibiotics as required~Exclusion Criteria:~* History of a major organ transplant or hematopoietic stem cell transplantation (HSCT)~* Participants with known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and/or immunosuppressants~* Known or suspected complement deficiency~* Laboratory abnormalities at screening, including:~  * Alanine aminotransferase \>2 x ULN (\>3 x ULN in case of patients with documented liver iron overload defined by serum ferratin values~    * 500 ng/ML)~ * Direct bilirubin \>2 x ULN (unless due to EVH or documented Gilbert's Syndrome)~* Current evidence of biliary cholestasis~* Estimated glomerular filtration rate of \<30 milliliters/minute/1.73 meter squared and/or are on dialysis~* Evidence of human immunodeficiency virus, hepatitis B, or active hepatitis C infection at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danicopan + C5 Inhibitor (Type: EXPERIMENTAL): Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
- Placebo + C5 Inhibitor (Type: PLACEBO_COMPARATOR): Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).